drugset / Trial / NCT03318978
Benzo[a]Pyrene Ultralow Dose-Response Study
Phase 0
Completed
8 enrolled
Oregon State University
Lawrence Livermore National Laboratory · collabNational Institute of Environmental Health Sciences (NIEHS) · collabPacific Northwest National Laboratory · collab
NaSingle-groupOpen-labelBasic science
Summary
Evaluation of the pharmacokinetics for \[14C\]-benzo\[a\]pyrene (\[14C\]-BaP) and metabolites in plasma and urine over 48 hours following 4 oral doses of 25, 50, 10 and 250 ng (2.7-27 nCi).
Timeline
- Start
- 2018-04-17
- Primary completion
- 2024-01-01
- Completion
- 2024-02-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | [14C]-benzo[a]pyrene | Unknown | 25 ng | Oral |
| Subject | [14C]-benzo[a]pyrene | Unknown | 50 ng | Oral |
| Subject | [14C]-benzo[a]pyrene | Unknown | 100 ng | Oral |
| Subject | [14C]-benzo[a]pyrene | Unknown | 250 ng | Oral |